Latest Lyrica Stories

MUMBAI and BALTIMORE, July 5, 2012 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of C.P. Pharmaceuticals C.V., LYRICA(R) (Pregabalin) capsules. Lupin's Pregabalin Capsules, 25 mg, 50...

Research findings may lead to new drugs designed to improve communication between brain cells and effectively treat neurological disorders Scientists at Weill Cornell Medical College have discovered that the single protein -- alpha 2 delta -- exerts a spigot-like function, controlling the volume of neurotransmitters and other chemicals that flow between the synapses of brain neurons. The study, published online in Nature, shows how brain cells talk to each other through these signals,...

NEW YORK, Oct. 28 /PRNewswire-FirstCall/ -- Pfizer Inc.(NYSE: PFE) announced today that the Japanese Ministry of Health, Labour and Welfare approved Lyrica® (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd. (Logo:...

WALTHAM, Mass., Jan. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a fibromyalgia drug that improves sleep quality more than Pfizer's Lyrica would earn a 38 percent patient share in the U.S. and a 30 percent patient share in Europe due to its efficacy, safety and tolerability, and delivery. However, U.S. and European physicians expect to use such a drug primarily as a second- or later-line...

WALTHAM, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although the majority of surveyed U.S. physicians prescribe Eli Lilly's Cymbalta and Pfizer's Lyrica for the treatment of fibromyalgia, neither agent has the majority of its uses in the first line. In the case of Cymbalta, surveyed rheumatologists report that 37 percent of their prescriptions for the drug are in the...

ANN ARBOR, Mich., Oct. 7, 2008 (GLOBE NEWSWIRE) -- Pipex Pharmaceuticals, Inc. (AMEX:PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that its double-blind, randomized, placebo-controlled phase II clinical trial of oral flupirtine for the treatment of fibromyalgia has received ethics committee approval to initiate the clinical trial. Fibromyalgia is a rheumatic pain...